VEGF levels in Tenon tissue linked to glaucoma surgery outcomes

Article

Vascular endothelial growth factor (VEGF) levels in the Tenon tissue and final IOP is significantly correlated to 1-year surgical outcomes of glaucoma surgery in patients with primary open-angle glaucoma (POAG)

Vascular endothelial growth factor (VEGF) levels in the Tenon tissue and final IOP is significantly correlated to 1-year surgical outcomes of glaucoma surgery in patients with primary open-angle glaucoma (POAG), claims an investigation in the Archives of Ophthalmology.

A group managed by Dr Hae-Young Lopilly Park, Department of Ophthalmology and Visual Science, Seoul St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, determined the levels of VEGF in the aqueous humour and the Tenon tissue in 19 POAG patients due to undergo glaucoma surgery. The study also included 17 control subjects due to undergo cataract surgery.

A 4x4 mm square of Tenon tissue was cut from the eye, along with the collection of 0.1 ml of aqueous humour. Enzyme-linked immunosorbent assay was used to analyse VEGF concentrations. Spearman correlation and regression analysis were conducted to evaluate the connection with VEGF levels and the clinical characteristics/postoperative IOP.

In POAG patients the VEGF in Tenon tissue was significantly increased, compared to the control group. Preoperative IOP was strongly related to the VEGF levels in Tenon tissue in both the univariate and the multivariate.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.